FDA Committees Will Consider COX-2 Benefits, Risks Feb. 16-18

  1. the food and drug administration (fda) has announced a joint public meeting of the agency's arthritis advisory committee and the drug safety and risk management advisory committee to be held february 16, 17 and 18, 2005.

    the committees will discuss the overall benefit-to-risk considerations (including cardiovascular and gastrointestinal concerns) for cox-2 selective non-steroidal anti-inflammatory drugs (nsaids) and related medicines. http://www.fda.gov/bbs/topics/news/2005/new01151.html


    can't wait to hear this meetings outcomes!
    •  

close